Gastric cancer kills roughly one million people annually worldwide, yet it remains chronically under-screened in Western primary care — largely because clinicians lack a clear, cost-justified protocol to layer bacterial testing onto existing cancer screening workflows. A modeling study published in JAMA now provides a quantitative economic rationale for changing that practice.
The cost-effectiveness analysis, authored by Lee and colleagues, evaluated what happens when a single Helicobacter pylori stool antigen test (HPSA) is appended to fecal immunochemical testing (FIT)-based colorectal cancer screening programs already in wide clinical use. Using decision-analytic modeling — a method that synthesizes probabilities, health outcomes, and costs across competing strategies under uncertainty — the investigators estimated that this combined approach would generate more life-years at lower total cost than FIT screening alone. The projected benefit derives primarily from reduced gastric cancer mortality attributable to detecting and eradicating H. pylori infection before precancerous lesions progress.
This finding sits at a meaningful intersection of infectious disease and oncology prevention. H. pylori is classified as a Group 1 carcinogen by the International Agency for Research on Cancer, and meta-analyses have consistently shown that eradication reduces gastric cancer incidence by roughly 35–50% in high-risk populations. What makes the JAMA analysis notable is its framing within an already-utilized screening infrastructure — FIT programs exist in many national guidelines, and adding a one-time stool antigen test requires minimal additional patient burden. That said, decision-analytic models are only as reliable as their input assumptions; key uncertainties include H. pylori prevalence in target populations, eradication success rates, and downstream compliance with follow-up endoscopy. The study does not replace a large randomized trial, and its conclusions will generalize most strongly to populations with moderate-to-high H. pylori prevalence. For health-conscious adults currently participating in colorectal screening, this analysis strengthens the case for asking their physician about concurrent H. pylori testing — a low-burden addition with potentially significant long-term benefit.